DCSS 0069 PDF

Weltevrede, Shell Inti. Morneau, Chevron; B. Foreman, ExxonMobil; S. De Vries, Invensys; T. Little,Halliburton; L. Ormerod, Weatherford; and A.

Author:Mogul Vosida
Country:Tunisia
Language:English (Spanish)
Genre:Software
Published (Last):5 July 2014
Pages:472
PDF File Size:17.85 Mb
ePub File Size:17.40 Mb
ISBN:773-4-16335-908-2
Downloads:35793
Price:Free* [*Free Regsitration Required]
Uploader:Gotaxe



Summarized below are the abstract titles that have been selected for oral or poster presentations. Once the posters are made public, they will be available on the Company's website in the Scientific Conferences section. Lenabasum is a rationally-designed, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 CB2. CB2 is preferentially expressed on activated immune cells, fibroblasts, muscle cells, and endothelial cells.

Lenabasum is also believed to have a direct effect on fibroblasts to limit production of fibrogenic growth factors and extracellular connective tissue that lead to tissue fibrosis scarring. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. Lenabasum has demonstrated promising activity in animal models of skin and lung inflammation and fibrosis in systemic sclerosis SSc. Lenabasum is also active in animal models of lung infection and inflammation in cystic fibrosis and joint inflammation and scarring in rheumatoid arthritis.

Lenabasum has demonstrated an acceptable safety and tolerability profiles in clinical studies to date. Lenabasum treatment was associated with improvement in multiple physician-assessed and patient-reported efficacy outcomes in Phase 2 studies in patients with diffuse cutaneous SSc and skin-predominant dermatomyositis. ACR CRISS score was the primary efficacy endpoint in the Phase 2 study of lenabasum in diffuse cutaneous SSc and showed a greater treatment effect in subjects who received lenabasum compared to placebo in that study.

Lenabasum treatment also was associated with a lower rate of and longer time to pulmonary exacerbations in a Phase 2 cystic fibrosis study. Corbus Pharmaceuticals Holdings, Inc. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 CB2 agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus is also developing a pipeline of drug candidates from more than novel compounds targeting the endocannabinoid system. The pipeline includes CRB, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 CB1 inverse agonist.

For more information, please visit www. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of and Section 21E of the Securities Exchange Act of and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature.

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms.

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. More Markets Why it's time for investors to go on defense. Premarket: 7 things to know before the bell. Top Stories 7 things to know before the bell. SoftBank and Toyota want driverless cars to change the world. Why it's time for investors to go on the defense.

Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of and Section 21E of the Securities Exchange Act of and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature.

More Markets. Top Stories.

IMAGINING INDIA NANDAN NILEKANI PDF

Log in to your subscription

Suppose that a number of items is put on operation and that their life times are identically exponentially distributed up to a time a , when the operating conditions change resulting in a different failure intensity of the exponential distribution for those items which have survived the change-point a. Predictions are made for the lifetime of operating items on condition of observed failures of a part of the items before and after the change-point a. The predictions are based on an Bayes approach, which is briefly introduced. Numerical examples are given to illustrate the results.

VIRTUOSO LAYOUT EDITOR USER GUIDE PDF

LCSA Letter 09-14: Updated Child Support Compliance Review ...

After careful thought and deliberation, and in consultation with Riverside County Public Health officials , Riverside County Child Support Services will close our lobbies to the public until further notice. We can assist you virtually anywhere. If you have specific Stimulus Payment questions, please visit our link here for updated frequently asked questions. We also want you to have confidence that we can assist you virtually anywhere, anytime by visiting our Live Chat option on our website. To activate our Live Chat, visit our website during regular business hours, and you can speak to a live agent to answer your child support questions.

GRAMIN BHANDARAN YOJANA PDF

Whom you provide child care. Child care provided during regular school sessions Page 1 of 2 B. SignNow's web-based software is specifically developed to simplify the organization of workflow and optimize the process of qualified document management. Use this step-by-step instruction to complete the Dcss form promptly and with ideal accuracy. By utilizing SignNow's complete solution, you're able to complete any needed edits to Dcss form, make your customized electronic signature in a couple of fast actions, and streamline your workflow without the need of leaving your browser.

ESTES EXPRESS BILL OF LADING PDF

Recommend Documents. Michigan law requires the FOC to review a child support order once every A review-re. Canadian Border. Support Child The State of Connecticut's child support program is designed to get your Support Child.

Related Articles